The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Overview of attention for article published in Diabetology & Metabolic Syndrome, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 29 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,983 followers.

RT @Miguel_A_Maria: The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Corona…

21 Nov 2022

Reply Repost Favourite

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial https://t.co/BxecZV2WtG https://t.co/5NHVQtHqVp

18 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.